GUIRGIS HANY DR EAR NOSE THROAT SPEBusiness Directories,Company Directories

Company Name: Corporate Name:	GUIRGIS HANY DR EAR NOSE THROAT SPE
Company Title:
Company Description:
Keywords to Search:
Company Address:	4040 Finch Ave E,SCARBOROUGH,ON,Canada
ZIP Code: Postal Code:	M1S
Telephone Number:	4162935511
Fax Number:
Website:
Email:
USA SIC Code(Standard Industrial Classification Code):	172970
USA SIC Description:	PHYSICIANS & SURGEON
Number of Employees:
Sales Amount:	Less than $500,000
Credit History: Credit Report:	Good
Contact Person:
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
GULESSERIAN PRECISION MACHINE
GUJARAT ABROAD
GUITAR SHACK & MUSIC EMPORIUM

Next company profile:
GUIRGIS, HANY MD
GUILDWOOD VILLAGE MONTESSORI SCHO
GUILDWOOD VILLAGE ANIMAL CLNC

Company News:

Lung Cancer - Medscape
Lung Cancer : Review in-depth clinical information, latest medical news, and guidelines on lung cancer, specifically small-cell lung cancer and non-small-cell lung cancer Read the latest
Small Cell Lung Cancer in 2024: Treatment Advances - Medscape
Amgen Drug Cuts Small Cell Lung Cancer Death Risk by 40%; Moving Earlier in the Disease Landscape: Understanding Adjuvant Immunotherapy for Non-Small Cell Lung Cancer 0 25 CME ABIM MOC Credits
ASCO 2025: Key Highlights in Advanced Lung Cancer - Medscape
In extensive-stage small cell lung cancer, tarlatamab demonstrated superiority over chemotherapy in the DeLLphi-304 trial, with favorable patient-reported outcomes including improved cough and
Advanced Non-Small Cell Lung Cancer Updates From ASCO 2024 - Medscape
Practice-changing studies in advanced non-small cell lung cancer presented at ASCO 2024 are reviewed by Dr Ticiana Leal, including the phase 3 LAURA and PALOMA-3 studies and a 5-year update of CROWN
Two Lung Cancer Drugs Recommended by EMA - Medscape
Is Consolidation Osimertinib Superior to Durvalumab in EGFR-Mutated Non–Small Cell Lung Cancer? Small Cell Lung Cancer in 2024: Treatment Advances 3090D553-9492-4563-8681-AD288FA52ACE
Why a New Inhalable Lung Cancer Treatment Is So Promising - Medscape
Evolving Treatment for Small Cell Lung Cancer; Fast Five Quiz: Small Cell Lung Cancer; SLIDESHOW Brain Lesions: Summaries of 12 Cases; Expert Commentary Why Lung Cancer Screening Is Not for
Changes in the Treatment Landscape of Early-Stage Non-Small Cell Lung . . .
Dr Narjust Florez explores the transformative shifts in the treatment landscape for early-stage non–small cell lung cancer over the years, particularly emphasizing the significant changes
Zenocutuzumab Effective Against NRG1 Fusion Cancers - Medscape
The bispecific antibody shows particularly promising results in non–small cell lung cancer (NSCLC) and pancreatic cancer patients, with responses lasting a median of 11 1 months
Potential Drivers of LCINS - Medscape
During a plenary session at the 2024 World Congress on Lung Cancer, experts addressed the known and suspected causes of LCINS, including fallout from climate change, vaping, cannabis use, and
Evaluation and Management of Small Pulmonary Nodules - Page 3 - Medscape
Lung nodules in the right lung and in the upper lobes have a higher probability for malignancy [ 17 , 45 ] Some studies indicate that 70% of all lung cancers are located in the upper lobes